Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

In situ immunopathological changes in cutaneous leishmaniasis due to Leishmania donovani.

Manamperi NH, Oghumu S, Pathirana N, de Silva MV, Abeyewickreme W, Satoskar AR, Karunaweera ND.

Parasite Immunol. 2017 Mar;39(3). doi: 10.1111/pim.12413.

PMID:
28112425
2.

Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.

Muniz AC, Bacellar O, Lago EL, Carvalho AM, Carneiro PP, Guimarães LH, Rocha PN, Carvalho LP, Glesby M, Carvalho EM.

J Infect Dis. 2016 Aug 15;214(4):570-6. doi: 10.1093/infdis/jiw196. Epub 2016 May 18.

PMID:
27190181
3.

Possibilities and challenges for developing a successful vaccine for leishmaniasis.

Srivastava S, Shankar P, Mishra J, Singh S.

Parasit Vectors. 2016 May 12;9(1):277. doi: 10.1186/s13071-016-1553-y. Review.

4.

The Nlrp3 inflammasome, IL-1β, and neutrophil recruitment are required for susceptibility to a nonhealing strain of Leishmania major in C57BL/6 mice.

Charmoy M, Hurrell BP, Romano A, Lee SH, Ribeiro-Gomes F, Riteau N, Mayer-Barber K, Tacchini-Cottier F, Sacks DL.

Eur J Immunol. 2016 Apr;46(4):897-911. doi: 10.1002/eji.201546015. Epub 2016 Jan 20.

5.

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP.

Antimicrob Agents Chemother. 2015 Jan;59(1):1-14. doi: 10.1128/AAC.04298-14. Epub 2014 Nov 3. Review.

6.

Comparison of immune regulatory factors in acute and chronic lesions of cutaneous leishmaniasis due to Leishmania major.

Hoseini SG, Javanmard SH, Hejazi SH, Rafiei L, Zarkesh SH, Karbalaii K, Khamesipour A.

J Res Med Sci. 2014 Mar;19(Suppl 1):S36-40.

7.

Regulatory T-cell profile in early and late lesions of cutaneous leishmaniasis due to Leishmania major.

Hoseini SG, Javanmard SH, Zarkesh SH, Khamesipour A, Rafiei L, Karbalaie K, Nilforoushzade M, Baghaei M, Hejazi SH.

J Res Med Sci. 2012 Jun;17(6):513-8.

8.
9.
10.

Effects of Leishmania major clones showing different levels of virulence on infectivity, differentiation and maturation of human dendritic cells.

Markikou-Ouni W, Ben Achour-Chenik Y, Meddeb-Garnaoui A.

Clin Exp Immunol. 2012 Sep;169(3):273-80. doi: 10.1111/j.1365-2249.2012.04611.x.

11.

Dynamic analysis of Th1/Th2 cytokine concentration during antiretroviral therapy of HIV-1/HCV co-infected patients.

Kang W, Li Y, Zhuang Y, Zhao K, Huang D, Sun Y.

BMC Infect Dis. 2012 Apr 25;12:102. doi: 10.1186/1471-2334-12-102.

12.
13.

IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection.

Anderson CF, Stumhofer JS, Hunter CA, Sacks D.

J Immunol. 2009 Oct 1;183(7):4619-27. doi: 10.4049/jimmunol.0804024. Epub 2009 Sep 11.

14.

Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Maurer-Cecchini A, Decuypere S, Chappuis F, Alexandrenne C, De Doncker S, Boelaert M, Dujardin JC, Loutan L, Dayer JM, Tulliano G, Arevalo J, Llanos-Cuentas A, Chizzolini C.

Infect Immun. 2009 May;77(5):2022-9. doi: 10.1128/IAI.01513-08. Epub 2009 Feb 23.

15.

Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes.

Meddeb-Garnaoui A, Zrelli H, Dellagi K.

Clin Exp Immunol. 2009 Feb;155(2):199-206. doi: 10.1111/j.1365-2249.2008.03821.x. Epub 2008 Nov 20.

16.

Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.

Murray HW.

Infect Immun. 2008 Sep;76(9):4088-91. doi: 10.1128/IAI.00490-08. Epub 2008 Jun 23.

17.

Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.

Zhang WW, Matlashewski G.

Infect Immun. 2008 Aug;76(8):3777-83. doi: 10.1128/IAI.01527-07. Epub 2008 May 12.

18.

Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis.

Carvalho LP, Passos S, Bacellar O, Lessa M, Almeida RP, Magalhães A, Dutra WO, Gollob KJ, Machado P, de Jesus AR.

Parasite Immunol. 2007 May;29(5):251-8.

19.

Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis.

Giudice A, Camada I, Leopoldo PT, Pereira JM, Riley LW, Wilson ME, Ho JL, de Jesus AR, Carvalho EM, Almeida RP.

BMC Infect Dis. 2007 Feb 22;7:7.

20.

CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis.

Anderson CF, Oukka M, Kuchroo VJ, Sacks D.

J Exp Med. 2007 Feb 19;204(2):285-97. Epub 2007 Feb 5.

Supplemental Content

Support Center